Denali Therapeutics Inc
NASDAQ:DNLI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
US |
Intrinsic Value
The intrinsic value of Denali Therapeutics Inc (DNLI) under the Base Case is 1.68 USD per share.
Compared with the current market price of 19.19 USD, the stock appears
Overvalued by 91% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Denali Therapeutics Does
Denali Therapeutics is a biotechnology company that designs drugs for diseases affecting the brain and nervous system, with a strong focus on conditions where medicines have a hard time reaching their target. Its main work is to discover and develop treatments for neurodegenerative and lysosomal storage diseases, which are serious disorders that can damage the brain and other organs over time.
- Headquarters
- United States of America US
- Employees
- 503
- IPO date
- Dec 8, 2017
Latest Earnings Call
- EPS
- −$0.68
- Expected
- −$0.72
- Surprise
- +5.6%
- Stock, next trading day
- +0.4%
Revenue & Expenses Breakdown
Denali Therapeutics Inc
Earnings Waterfall
Denali Therapeutics Inc
The intrinsic value for Denali Therapeutics Inc (DNLI) under the Base Case is 1.68 USD.
Compared with the current market price of 19.19 USD, the stock appears Overvalued by 91% .